Rubicon Research Limited has scheduled an earnings conference call for Friday, August 14, 2026, at 6:00 PM IST, to discuss the company's financial performance for the quarter ended June 30, 2026. The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Company Secretary Deepashree Tanksale on August 7, 2026.

Senior Management Representation

The Q1FY27 earnings concall will be represented by the following senior management members:

• Mr. Parag Sancheti – Chief Executive Officer
• Mr. Nitin Jajodia – Chief Financial Officer
• Mr. Sagar Oak – Senior Vice President, Corporate Development & Strategy

The call will be moderated by Tushar Manudhane, Executive Director – Healthcare at Motilal Oswal Financial Services, serving as the Call Leader.

Conference Call Schedule

The earnings call is scheduled across multiple time zones to facilitate participation from investors and stakeholders globally. The following table outlines the call timings by region:

Dial-In Details

Participants can join the conference call using the following dial-in numbers:

An Express Login option via Diamond Pass is also available for participants seeking direct access to the call. The conference call will cover the company's financial performance for the quarter ended June 30, 2026, along with a discussion on the way forward as presented by senior management.

Rubicon Research Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 with BSE Limited and the National Stock Exchange of India Limited, pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report forms part of the company's Integrated Annual Report for FY 2025-26 and is prepared on a standalone basis. The filing was signed by Deepashree Tanksale, Company Secretary and Compliance Officer.

Company Overview and Financial Profile

Rubicon Research Limited, incorporated in 1999 and registered at MedOne House, B-75, Road No. 33, Wagle Estate, Thane – 400 604, Maharashtra, is engaged in pharmaceutical formulations. The company develops, manufactures, and markets branded specialty and generic pharmaceutical products, with pharmaceutical products accounting for 100% of its turnover.

Key financial and operational parameters for FY 2025-26 are summarised below:

The company primarily markets its products in the United States through subsidiaries Validus Pharmaceuticals LLC and AdvaGen Pharma, as well as through third-party sales and marketing entities. Its customer base includes wholesalers, major pharmacy chains, group purchasing organizations (GPOs), regional and national pharmacy networks, and Managed Care Organizations.

Operations and Workforce

As of the end of FY 2025-26, the company operated 3 plants and 2 offices domestically, and 7 international offices, serving customers across 8 countries. The company's workforce comprised 1,303 total employees and 582 total workers.

On board-level representation, the company's Board of Directors comprised 8 members, of whom 2 (25%) were women. Among Key Management Personnel, 1 out of 2 (50%) was a woman. The company's highest authority for implementation and oversight of the Business Responsibility policy is Mr. Parag Sancheti, Executive Director & CEO.

Governance, Ethics, and Compliance

Rubicon Research has established policies covering all nine Principles of the National Guidelines on Responsible Business Conduct (NGRBCs). These policies have been approved by the Board and are available on the company's website at www.rubicon.co.in/investors . The company reported nil fines, penalties, or disciplinary actions against directors, KMPs, employees, or workers for bribery or corruption in FY 2025-26, and nil complaints related to conflict of interest.

The Board of Directors, through its Audit Committee and Risk Management Committee, oversees sustainability-related matters. Compliance with all applicable statutory requirements is reviewed by the Board and the Audit Committee on a quarterly basis. The company has also identified ten material responsible business conduct and sustainability issues, including corporate governance and business ethics, innovation and research, human capital development, product quality and safety, cybersecurity and data privacy, supply chain management, waste management, energy efficiency and climate change, occupational health and safety, and enhancing accessibility of medicines.

Environmental Initiatives and Sustainability Targets

The company has implemented Zero Liquid Discharge (ZLD) mechanisms at select manufacturing facilities, with treated water reused for cooling tower make-up and gardening. No liquid effluent is discharged to surface water or any water body from any location.

Key air emission data is provided below:

The company has set the following environmental targets under Principle 6:

• Increase the use of renewable energy by 30% through installed solar systems and group captive power consumption by 2030
• Enhance green cover and biodiversity through increased tree plantation at Ambernath, Satara, and Indore manufacturing plants
• Achieve water neutrality by 2030
• Ensure 100% disposal of hazardous waste through authorised pre-processing/co-processing facilities by 2030

Notable sustainability initiatives undertaken include solar rooftop installations at Satara and Ambernath plants generating total renewable electricity of 1,400.20 GJ in FY 2025-26, transition of hazardous waste from incineration/landfill to co-processing, procurement of renewable energy from third-party captive plants (expected to constitute at least 40% of energy mix at Ambernath plant), LED lighting and Variable Frequency Drives (VFDs) deployment across locations, and digitalization reducing paper consumption by 25%.

CSR, Stakeholder Engagement, and Consumer Responsibility

CSR is applicable to Rubicon Research under Section 135 of the Companies Act, 2013. The company conducts CSR activities through its internal platform, "Sankalp", focusing on healthcare, education, sanitation, cleanliness, and community welfare. Beneficiaries of CSR projects in FY 2025-26 included 35 students through a contribution to Aarambha Foundation, 500 students through a contribution to a Kitchen and Dining Hall, and 1,950 beneficiaries through a contribution to Shree Santkrupa Shikshan Sanstha, among others.

On consumer responsibility, the company reported nil voluntary or forced product recalls during FY 2025-26, nil data breaches, and no instances of disruption or discontinuation of essential services. The company is affiliated with one trade and industry body — the Bombay Chamber of Commerce & Industry (BCCI). Rubicon Research is currently focused on managing Scope 1 and Scope 2 emissions, with efforts to identify and disclose Scope 3 emissions planned for upcoming reporting cycles. Independent assurance of the BRSR report is not applicable for FY 2025-26.